Latest News

New Investigator-Initiated Study to Test CYR-064 for Hyposmia in Parkinson Disease
New Investigator-Initiated Study to Test CYR-064 for Hyposmia in Parkinson Disease

February 8th 2025

The 32-week study will enroll 15–20 adults aged 18–80 with Parkinson's-related hyposmia, featuring a 24-week treatment period of twice-daily CYR-064 nasal sprays.

Endovascular Thrombectomy Provides No Additional Benefit in Medium Vessel Occlusion Stroke, ESCAPE-MeVO Results Show
Endovascular Thrombectomy Provides No Additional Benefit in Medium Vessel Occlusion Stroke, ESCAPE-MeVO Results Show

February 8th 2025

NeurologyLive® Friday 5 — February 7, 2024
NeurologyLive® Friday 5 — February 7, 2024

February 7th 2025

Episode 134: Previewing the 2025 ACTRIMS Forum
Episode 134: Previewing the 2025 ACTRIMS Forum

February 7th 2025

Jonathan Rubin, MD, MBA  (Credit: Supernus Pharmaceuticals)
Insights on the Newly Approved Subcutaneous Infusion Therapy for Parkinson Disease

February 6th 2025

Coverage of the International Stroke Conference 2025

Get direct access to interviews with experts, as well as the latest data and clinical news updates, straight from the conference floor in Los Angeles.

ISC 2025

Conference Coverage

View All
Endovascular Thrombectomy Provides No Additional Benefit in Medium Vessel Occlusion Stroke, ESCAPE-MeVO Results Show
Endovascular Thrombectomy Provides No Additional Benefit in Medium Vessel Occlusion Stroke, ESCAPE-MeVO Results Show

February 8th 2025

Clarisse Goas MSN, APRN-CNP
Using Practical Training to Enhance Movement Disorder Care: Clarisse Goas MSN, APRN-CNP

February 7th 2025

Wayne Feng, MD, MS  (Credit: Duke University School of Medicine)
Mild Electrical Brain Stimulation Fails to Boost Poststroke Recovery in Phase 2 Study

February 6th 2025

 Brent Forester, MD, MSc
Clarifying the Role of Cannabinoids in Agitation Management for Alzheimer Disease: Brent Forester, MD, MSc

February 2nd 2025

Video Series
Video Interviews
Podcasts

Most Recent

© 2025 MJH Life Sciences

All rights reserved.